License pathogen reduction technology (PRT) for red blood cell (RBC) components to reduce the risk of transfusion-transmitted infection (TTI) by recognized, emerging, epidemic, and endemic pathogens…

Active Definitive Contract Awarded Last action

Contract number
75A50124C00046
Awardee
Awarding agency
Obligated
$65,358,564

Award facts

Opportunity
Contract value 31% obligated
  • $65,358,563.95 Current, with exercised options
  • $209,038,158.15 Potential, with all options
Completion date 30% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Sharing
Place of performance
Concord, CA 94520, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00003 · Supplemental funding to the base period (clin 0001, clin 0002 & clin 0003); exercise option 1 (clin 0004); update travel budget; update go/no-go milestones;… $33,237,041
Other Administrative Action P00002 · Cerus - no-cost modification is to update article G.2. Contracting officer to add julie bergmann as the alternate contracting officer's representative (ACOR),… $0
Supplemental Agreement for work within scope P00001 · No-cost modification is to update article G.1. Contracting officer to reflect richard a. Hall as the contracting officer. $0
Original award $32,121,523

About this award

Written by GovTribe AI ·

The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract to Cerus Corporation for licensing pathogen reduction technology for red blood cell components to reduce transfusion-transmitted infection risk on September 30, 2024, with a ceiling value of $209.038 million under cost-sharing pricing.

The contract provides supplemental funding to the base period and exercises Option 1, with updates to travel budget, go/no-go milestones, indirect rates, and the Change of Approach threshold to $350,000. Performance continues through September 30, 2031, at the company's facility in Concord, California.

The originating solicitation, posted by BARDA in September 2023, solicited advanced research and development proposals for medical countermeasures against chemical, biological, radiological, and nuclear threats, pandemic influenza, and emerging infectious diseases. The government description specifies development of pathogen reduction technology capable of treating over ten million red blood cell components. The opportunity operates under a three-stage process with a final proposal deadline of September 25, 2028, and contemplates multiple awards of various values and contract types on a full-and-open basis with no set-aside designations. Place of performance is Concord, CA.

Description

As the agency reported it.

License pathogen reduction technology (PRT) for red blood cell (RBC) components to reduce the risk of transfusion-transmitted infection (TTI) by recognized, emerging, epidemic, and endemic pathogens that is capable of treating over 10 million RBC COM

Quick answers

Who was awarded contract 75A50124C00046?

75A50124C00046 was awarded to Cerus Corporation by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 30, 2024.

How much is contract 75A50124C00046 worth?

The government has obligated $65,358,564 on 75A50124C00046. Its potential value, with all options, is $209,038,158.

Was contract 75A50124C00046 competed?

The extent of competition for 75A50124C00046 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login